SAN DIEGO, March 18, 2019
/PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading
commercial provider of liquid biopsy tests designed to provide
physicians with clinically actionable information to improve the
outcomes of patients diagnosed with cancer, announces that it has
been awarded Japanese Patent No. 6463668 entitled, DEVICES AND
METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers a
microchannel device and antibodies for the capture of rare cells of
interest, including CTCs that are shed into the blood stream by
solid tumors. Biocept believes the newly granted patent has claims
that encompass any biological sample type of interest, and is the
32nd patent issued to Biocept that is core to its liquid
biopsy technology platforms.
"The granting of this patent further expands internationally
Biocept's platform for capturing and analyzing rare cells from
biological fluids, such as blood, bone marrow, cerebral spinal
fluid (CSF), and tissue, to assess the status of patients with
cancer," said Lyle Arnold, Ph.D.,
Chief Scientific Officer at Biocept. "This technology
interfaces well with Biocept's other patented liquid biopsy
technologies, including the Company's blood collection tube, and
ctDNA analysis platform for providing information to aid physicians
in the treatment of their patients with cancer."
The technology covered by this issued patent combines Biocept's
patented microchannel platform together with antibodies to enable
the capture of rare cells of interest. These technologies combine
to enable the capture of cells that are present in very low numbers
from blood and other biological fluids.
Michael Nall, Biocept's President
and CEO, added, "Obtaining this new patent provides additional
intellectual property protection for the unique and novel features
of our Target Selector™ platform, featuring our microchannel
and antibody capture technologies for CTCs and other rare cells of
interest. We believe that additional global intellectual property
expands the opportunity for Biocept to generate revenue in
territories outside the U.S."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the utility of our
intellectual property protections, and our ability to expand
opportunities to generate sales in territories outside the U.S.,
such statements are forward-looking, and are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risk factors as set forth in our Securities and
Exchange Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at http://www.sec.gov.
Investor Contact:
LHA
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-awarded-patent-in-japan-for-the-capture-of-rare-cells-including-ctcs-from-any-biological-sample-of-interest-with-a-microchannel-device-300813516.html
SOURCE Biocept, Inc.